Phreesia added $12.2 million of revenue in the three months ended July 31, 2026. Accounts receivable added $12.6 million. That is a neat little scale comparison, and not quite the one a growth investor would frame on a poster.
The income statement was plainly better. Revenue reached $129.5 million, operating income swung from a $1.5 million loss to $7.6 million, and operating cash flow rose to $18.3 million from $14.8 million a year earlier. The company also spent far less on reported capex, which fell 72.2% to $492,000.
The complication is inside the revenue mix. Subscription and related-services revenue from healthcare services organizations, the line most closely associated with Phreesia’s core healthcare offering, fell even as total revenue rose. Network solutions did the heavier lifting.
Management described that split this way:
"The increase was primarily driven by network solutions revenue growth that outpaced AHSC growth."
Phreesia, Form 10-Q, September 3, 2026
In plain English, Phreesia’s growth arrived from the network line rather than from healthcare services organizations. That matters because the headline revenue increase is not a single, uniform engine.
The company also disclosed a decline in the healthcare-services subscription line, from $53.7 million to $52.7 million. Management attributed it primarily to one-time adjustments for non-recurring fees and less one-time revenue recognition from license delivery:
"Our subscription and related services revenue from healthcare services organizations decreased $1.0 million to $52.7 million for the three months ended July 31, 2026, as compared to $53.7 million for the three months ended July 31, 2025, primarily due to one-time adjustments for non-recurring fees and a decline in one-time revenue recognition from license delivery."
Phreesia, Form 10-Q, September 3, 2026
That explanation gives the decline a finite accounting shape, but it does not turn the subscription line into growth. The next quarterly report’s comparison of healthcare-services subscription revenue and accounts receivable will show whether this mix and collection pattern persisted.
Margins improved sharply, with operating margin moving from negative 1.3% to 5.9%. Research and development spending fell 5.8%, stock compensation fell 26.8%, and labor costs were lower, although other third-party costs rose $3.3 million. The company did not buy that operating improvement with a large equipment program.
Cash generation improved too, though less dramatically relative to earnings. Operating cash flow rose 23.5%, while cash conversion fell from 22.68 times net income to 9.56 times because net income grew much faster. That is the difference between producing more cash and making the income statement look much larger.
Phreesia’s own annual record shows the longer arc: revenue reached $467.8 million in the year ended January 31, 2026, while operating margin was still negative 1.4%. At the latest close of $11.88, the company had $71.2 million of net cash, but its reported P/E was 316.8x. Operating income is now positive, while net income was $1.9 million, still small relative to the price tag attached to them.
The three-month filing therefore offers two clean facts at once: operating income turned positive, and the core healthcare-services subscription line declined. More revenue, less of the recurring-looking stuff. Business arithmetic, with an asterisk.
Phreesia’s three-month results show network solutions growth outpacing healthcare-services organization growth while operating margin turned positive.